NCT06950515 General Anesthesia vs Conscious Sedation for Radial Endobronchial Ultrasound
| NCT ID | NCT06950515 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institut universitaire de cardiologie et de pneumologie de Québec, University Laval |
| Condition | Lung Cancers |
| Study Type | INTERVENTIONAL |
| Enrollment | 306 participants |
| Start Date | 2025-09-25 |
| Primary Completion | 2027-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 306 participants in total. It began in 2025-09-25 with a primary completion date of 2027-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The endoscopic investigation of lung lesions is experiencing significant growth with the increasing number of lung cancer screening programs. Peripheral endobronchial ultrasound (pEBUS) is the most widely used endoscopic technique in the investigation of peripheral pulmonary lesions (PPL). It is performed in relatively equal proportions under conscious sedation and general anesthesia by interventional pulmonologists throughout the world. Users of conscious sedation justify themselves by the fewer resources consumed and the absence of demonstration of a superior diagnostic yield of general anesthesia while users of general anesthesia claim diagnostic yield and comfort for the patient are superior with their approach. Our main objective is to compare the diagnostic yield of pEBUS under general anesthesia to that obtained under conscious sedation.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years and ability to consent * Peripheral lung lesion less than 5cm in average diameter on axial CT images (A lung lesion will be considered peripheral if it is located beyond the origin of the subsegmental bronchi and presumed not to be visible endoscopically in white light during the evaluation of the CT scan by an interventional pulmonologist.) * Lesion deemed accessible by pEBUS by an experienced interventional pulmonologist * Decision by the medical team and the patient to use pEBUS as a diagnostic modality for the lung lesion Exclusion Criteria: * Planned use of electromagnetic navigation, augmented fluoroscopy or robotic bronchoscopy in addition to pEBUS. The use of virtual bronchoscopy planning is permitted * Presence of suspicious lymph nodes (size ≥ 10mm and/or moderate or greater hypermetabolism) on imaging which are accessible by l-EBUS and for which rapid on-site cytological analysis will be used * Contraindication to bronchoscopy or biopsies such as an unstable medical condition or uncorrected coagulopathy * Current pregnancy * Lack of free and informed consent
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06950515 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Cancers. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06950515 currently recruiting?
Yes, NCT06950515 is actively recruiting participants. Contact the research team at marc.fortin@criucpq.ulaval.ca for enrollment information.
Where is the NCT06950515 trial being conducted?
This trial is being conducted at Québec, Canada.
Who is sponsoring the NCT06950515 clinical trial?
NCT06950515 is sponsored by Institut universitaire de cardiologie et de pneumologie de Québec, University Laval. The trial plans to enroll 306 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.